SchapiraA.H., and TolosaE. (2010). Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol., 6, 309–317.
2.
OlanowC.W., and SchapiraA.H. (2008). Parkinson's disease and other movement disorders, in: Harrison's Principles Internal Medicine, Vol 2., 18th ed. New York: McGraw-Hill, pp. 3317–3327.
3.
HuangY.Y., SharmaS.K., CarrollJ., and HamblinM.R. (2011). Biphasic dose response in low level light therapy - an update. Dose Response., 9, 602–618.
4.
ShawV.E., SpanaS., AshkanK., BenabidA.L., StoneJ., BakerG.E., and MitrofanisJ. (2010). Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment. J. Comp. Neurol., 518, 25–40.
5.
ShawV.E., PeoplesC., SpanaS., AshkanK., BenabidA.L., StoneJ., BakerG.E., and MitrofanisJ. (2012). Patterns of cell activity in the subthalamic region associated with the neuroprotective action of near-infrared light treatment in MPTP-treated mice. Parkinsons Dis. 296875, 1–9. doi: 10.1155/2012/296875.
6.
PeoplesC., SpanaS., AshkanK., BenabidA.L., StoneJ., BakerG.E., and MitrofanisJ. (2012). Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson's disease. Parkinsonism Relat. Disord., 18, 469–476.
7.
LiangH.L., WhelanH.T., EellsJ.T., and Wong-RileyM.T. (2008). Near-infrared light via light-emitting diode treatment is therapeutic against rotenone- and 1-methyl-4-phenylpyridinium ion-induced neurotoxicity. Neuroscience, 153, 963–974.
8.
TrimmerP.A., SchwartzK.M., BorlandM.K., De TaboadaL., StreeterJ., and OronU. (2009). Reduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy. Mol. Neurodegener., 4, 1–11.